From metrological comparability to clinical continuity: authorising laboratory result reporting when changing measurement procedures

OBJECTIVES: To develop and apply an operational framework integrating metrological, analytical, clinical and risk evidence to authorise an output-specific reporting rule after a change in measurement procedure. METHODS: Four measurement procedure changes were evaluated: alanine aminotransferase (ALT) procedures with and without pyridoxal-5'-phosphate activation; follicle-stimulating hormone (FSH) reagent replacement; routine vs. short-turnaround-time (STAT) parathyroid hormone (PTH) procedures; and tacrolimus procedure replacement with retention of the previous procedure for contingency use. The pathway integrated metrological comparability and compatibility, operational equivalence, controlled correction to a target reporting scale, independent clinical verification, uncertainty-aware classification, risk assessment and surveillance. RESULTS: The framework produced four qualitatively distinct outcomes: no cross-procedure continuity for ALT; direct continuity for raw FSH results; PTH continuity only through a corrected STAT result; and routine use of the new tacrolimus procedure, with the previous one restricted to contingency testing. FSH showed 100 % pair-level compatibility (95 % CI 91.2-100 %) and nominal percentage of clinically acceptable concordance (PCAC) of 96.6 % (82.2-99.9 %). PTH raw compatibility was assumption-sensitive at 90.0 % (76.3-97.2 %) vs. 87.5 % (73.2-95.8 %); the corrected output increased compatibility to 95.0 % (83.1-99.4 %), with nominal PCAC of 100 % (83.2-100 %). Tacrolimus met the mean-difference criterion but showed excess residual scatter, raw compatibility of 70.0 % (53.5-83.4 %) and nominal PCAC of 65.0 % (40.8-84.6 %); exploratory correction was not authorised. CONCLUSIONS: Changes in measurement procedure should culminate in an authorised reporting rule integrating metrological, analytical, clinical and risk evidence. Regression alone cannot establish continuity or interchangeability.

Authors

Institutions

Publication Details

Journal
Clinical Chemistry and Laboratory Medicine (CCLM)
Published
2026-08-27
DOI
https://doi.org/10.1515/cclm-2026-1271
Primary Topic
Clinical Laboratory Practices and Quality Control
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

From metrological comparability to clinical continuity: authorising laboratory result reporting when changing measurement procedures

Virgínia Mas-Bosch, Míriam Valbuena-Asensio, Aurora Blanco-Font, David Ceacero-Marín et al.
Clinical Chemistry and Laboratory Medicine (CCLM)
Clinical Laboratory Practices and Quality Control
article

From metrological comparability to clinical continuity: authorising laboratory result reporting when changing measurement procedures

Virgínia Mas-Bosch, Míriam Valbuena-Asensio, Aurora Blanco-Font, David Ceacero-Marín, Raúl Rigo-Bonnin
article en

Abstract

OBJECTIVES: To develop and apply an operational framework integrating metrological, analytical, clinical and risk evidence to authorise an output-specific reporting rule after a change in measurement procedure. METHODS: Four measurement procedure changes were evaluated: alanine aminotransferase (ALT) procedures with and without pyridoxal-5'-phosphate activation; follicle-stimulating hormone (FSH) reagent replacement; routine vs. short-turnaround-time (STAT) parathyroid hormone (PTH) procedures; and tacrolimus procedure replacement with retention of the previous procedure for contingency use. The pathway integrated metrological comparability and compatibility, operational equivalence, controlled correction to a target reporting scale, independent clinical verification, uncertainty-aware classification, risk assessment and surveillance. RESULTS: The framework produced four qualitatively distinct outcomes: no cross-procedure continuity for ALT; direct continuity for raw FSH results; PTH continuity only through a corrected STAT result; and routine use of the new tacrolimus procedure, with the previous one restricted to contingency testing. FSH showed 100 % pair-level compatibility (95 % CI 91.2-100 %) and nominal percentage of clinically acceptable concordance (PCAC) of 96.6 % (82.2-99.9 %). PTH raw compatibility was assumption-sensitive at 90.0 % (76.3-97.2 %) vs. 87.5 % (73.2-95.8 %); the corrected output increased compatibility to 95.0 % (83.1-99.4 %), with nominal PCAC of 100 % (83.2-100 %). Tacrolimus met the mean-difference criterion but showed excess residual scatter, raw compatibility of 70.0 % (53.5-83.4 %) and nominal PCAC of 65.0 % (40.8-84.6 %); exploratory correction was not authorised. CONCLUSIONS: Changes in measurement procedure should culminate in an authorised reporting rule integrating metrological, analytical, clinical and risk evidence. Regression alone cannot establish continuity or interchangeability.

Clinical Chemistry and Laboratory Medicine (CCLM)
Bellvitge University Hospital (ES)
Openalex Percentile: Top 10%
Clinical Laboratory Practices and Quality Control
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.